Antipodes Asia Fund
Fund overview
The Antipodes Asia Fund is an actively managed Asia (ex-Japan) equities fund designed to deliver long-term capital growth. The Fund primarily invests in equity securities of companies listed on securities exchanges across the Asia (ex-Japan) region.
To support its investment objective, the Fund may also gain exposure to companies listed outside the Asia (ex-Japan) region that have significant assets, investments, production activities, trading or other business interests in the region, or that derive a significant portion of their revenue from Asia (ex-Japan). The Fund may additionally invest in unlisted instruments with equity-like characteristics, such as participation notes and convertible bonds.
The Fund combines rigorous fundamental research with disciplined stock selection and typically holds a diversified portfolio. Investors should expect higher volatility as part of the Fund’s return profile.This product is classified as a Hedge Fund under ASIC Regulatory Guide RG240 and may have complex features. This product is likely to be suitable for investors who have received personal advice.
Ratings
Performance chart
Cumulative performance (over selected time horizon)
Returns greater than 1 year are annualised. Past performance is no indication of future performance. Calculations are based on exit price with distributions reinvested
Net performance
The Fund was previously known as the Premium Asia Fund. Antipodes Partners Limited became the Investment Manager of the Fund effective 22 April 2024.
Key facts
1The portfolio allocation ranges provided are indicative only. The Fund will be rebalanced within a reasonable period of time should the exposure move outside these ranges.
The publication of unit prices from 1st July 2025 onwards will be delayed while annual distribution amounts are finalised. The unit prices for 30th June 2025 are cum distribution and are reflective of fund performance to that date.
Unit price history
Distribution history
Portfolio profile as at 31st October 2026
Top 10 equity longs (%)
Sector exposure (%)2
Regional exposure (%)1, 3
1 Where possible, regions, countries and currencies classified on a look through basis. 2 GICS Classification. 3 Antipodes Partners classification.
Invest
If you are applying using paper application forms, the minimum investment in the Antipodes Asia Fund is $25,000 for new investors and $10,000 for existing investors.
This fund is open to investors from Australia and New Zealand.
It is a legal requirement to download and read the Product Disclosure Statement before proceeding and we recommend that you consult a licensed financial advisor before making investment decisions.
Download Product Disclosure Statement (PDS).
Download Product Disclosure Statement (PDS) – NZ.
Download Target Market Determination (TMD).
The application below allows you to invest in the Antipodes Asia Fund.
If you are applying using paper application forms, the minimum investment in the Antipodes Asia Fund is $25,000 for new investors and $10,000 for existing investors.
Purchase, top-up or sell a managed fund investment the familiar way.
- Download an application form here
- Complete the application form & sign
- Provide certified copies of your identity to verify your identity
- Email service@pinnacleinvestment.com
Benefits of investing in the Antipodes Asia Fund
- Regional exposure: Access a carefully selected portfolio of Asian companies often unavailable to retail investors.
- Professional management: Experienced team leveraging a disciplined investment process aimed at achieving absolute returns above the benchmark over a full market cycle.
- Aligned interests: Antipodes is majority owned by its investment team with a performance culture underpinned by sensible incentives, ensuring our goals align with yours.
- Robust investment process: Comprehensive, integrated investment approach and process.
Who is this fund for?
- Investors seeking long-term capital growth through exposure to equities in the Asia (ex-Japan) region.
- Those comfortable with high or very high risk and a minimum investment horizon of 5 years.
- Investors looking to use the fund as a minor or satellite allocation within a diversified investment portfolio.
Meet the Portfolio Managers
Key fund information
Strategy
Asia Equity
Strategy inception date
December 2009
Investment objective
The Fund aims to generate positive returns, consisting of both capital growth and income, over a three to five-year period prior to accounting for movements in currency exchange rates
Benchmark
MSCI All Country Asia ex Japan Net Index in AUD
Suggested minimum investment period
5 years
Minimum initial investment
A$25,000
Management fee
1.20% p.a. of the NAV of the Fund
Performance fee
15% of net return in excess of the benchmark
Frequently asked questions
Is Asia a good investment?
Investing in Asia can offer strong long-term growth potential due to rapidly expanding economies, rising consumer demand, and innovative companies. An Asia fund investment, like the Antipodes Asia Fund, provides diversified exposure to high-quality Asia equities, helping investors access opportunities often unavailable through individual stocks or passive ETFs. However, investors should be aware that markets in the region can be volatile and require a long-term perspective.
How does the Antipodes Asia Fund compare to other Asia funds?
Among the best Asia funds, the Antipodes Asia Fund stands out due to its active management, rigorous research, and focus on undervalued Asia equities. Unlike passive funds the portfolio is constructed based on conviction rather than market weightings.
How often are Antipodes Asia Fund distributions paid?
Distributions for the Antipodes Asia Fund are paid once a year, at the end of the financial year (30 June).
Important information
This information has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Antipodes Asia Fund (ARSN 134 226 029) (‘Fund’). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Antipodes Asia Fund. MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526).
This website contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.
Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks referred to may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at www.antipodes.com or by calling 1300 097 995.
The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating assigned Antipodes Asia Fund (MAQ0635AU) – October 2025 referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.
The rating issued 03/2026 for the Antipodes Asia Fund (MAQ0635AU) is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2026 Lonsec. All rights reserved.